ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
ORIC Pharmaceuticals (Nasdaq: ORIC) announced two late-breaking oral presentations of Phase 1b data for enozertinib (ORIC-114) at the ESMO Asia Congress 2025 in Singapore (December 5–7, 2025).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ORIC Pharmaceuticals (Nasdaq: ORIC) announced two late-breaking oral presentations of Phase 1b data for enozertinib (ORIC-114) at the ESMO Asia Congress 2025 in Singapore (December 5–7, 2025).
The mini-oral (LBA15) on Dec 5, 2025 at 11:38–11:43 a.m. SGT covers previously treated EGFR atypical mutant NSCLC with randomized dose optimization and CNS activity. The proffered paper oral (LBA13) on Dec 6, 2025 at 10:02–10:12 a.m. SGT covers EGFR exon 20 mutant NSCLC in previously treated and treatment-naïve patients. ORIC will host a conference call and webcast on Dec 6, 2025 at 8:00 p.m. ET, with a replay available for 90 days.
Details
News Market Reaction – ORIC
On Dec 4, the first trading day after this news, ORIC closed 3.73% above the previous close.
Data tracked by StockTitan Argus for the Dec 4 session.
Key Figures
- Mini-oral number
- LBA15
- EGFR atypical mutant NSCLC mini-oral at ESMO Asia Congress 2025
- Proffered paper number
- LBA13
- EGFR exon 20 mutant NSCLC proffered paper at ESMO Asia Congress 2025
- Mini-oral time
- 11:38–11:43 a.m. SGT
- Mini-oral session on December 5, 2025
- Proffered paper time
- 10:02–10:12 a.m. SGT
- Proffered paper session on December 6, 2025
- Conference call time
- 8:00 p.m. ET
- ORIC conference call and webcast on December 6, 2025
- Conference dates
- December 5–7, 2025
- ESMO Asia Congress 2025 in Singapore
- Webcast replay period
- 90 days
- Replay availability after December 6, 2025 conference call
- 52-week range
- $3.8951–$14.93
- 52-week low and high before this news
Historical Context
-
Phase 1b enozertinib EGFR exon 20 data with strong systemic and CNS activity.
-
Inducement stock options and RSUs granted to new non-executive employees.
-
Phase 1b enozertinib data in HER2 exon 20 NSCLC with notable disease control.
-
Enozertinib Phase 1b data in EGFR atypical NSCLC showing strong CNS activity.
-
Announcement of late-breaking enozertinib oral presentations and investor call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
her2 medical
nsclc medical
cns medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET
SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two late-breaking oral presentations highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The mini-oral presentation will focus on data in previously treated patients with EGFR atypical mutant NSCLC, and the proffered paper oral presentation will focus on data in previously treated and treatment-naïve patients with EGFR exon 20 mutant NCSLC.
| Mini-oral presentation details: | |
| Title: | Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in Previously Treated NSCLC with EGFR Atypical Mutations: Randomized Dose Optimization and CNS Activity |
| Presentation Number: | LBA15 |
| Session Type and Title: | Mini Oral session 1: Thoracic malignancies |
| Lecture Date and Time: | Friday, December 5, 2025; 11:38 – 11:43 a.m. SGT |
| Proffered paper oral presentation details: | |
| Title: | Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in EGFR Exon 20 Mutant NSCLC: Randomized Dose Optimization and CNS Activity |
| Presentation Number: | LBA13 |
| Session Type and Title: | Proffered Paper session: Thoracic malignancies |
| Lecture Date and Time: | Saturday, December 6, 2025; 10:02 – 10:12 a.m. SGT |
Full late-breaking abstracts are available for public viewing via the ESMO Asia Congress website.
Conference Call and Webcast Details
In conjunction with the ESMO Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib (ORIC-114), a brain-penetrant inhibitor that selectively targets EGFR exon 20, EGFR atypical, and HER2 exon 20 mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.